# Alethia Biotherapeutics

Source: https://onco.cc/companies/alethia-biotherapeutics/  
OnCo record `alethia-biotherapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Alethia Biotherapeutics is a Montreal biotech whose antibody sotevtamab (AB-16B5) blocks secreted clusterin, a protein that lets lung and other cancers change shape, spread and resist treatment.

## Summary

Alethia Biotherapeutics develops sotevtamab (AB-16B5), a humanised antibody against secreted clusterin, a chaperone protein that promotes epithelial-to-mesenchymal transition. Blocking it is intended to keep tumour cells in an epithelial state that responds better to chemotherapy and immunotherapy. Sotevtamab is in a phase 2 trial with docetaxel in non-small cell lung cancer after platinum and checkpoint therapy, and has been studied in other solid tumours.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Alethia Biotherapeutics Inc.
- Tags: drug-maker
- HQ: Montreal
- Type: biotech

## Connected records

- drugs: [Sotevtamab](https://onco.cc/drugs/sotevtamab/)

---
JSON: https://onco.cc/api/v1/entities/alethia-biotherapeutics.json